Interestingly, genetic modification of MSCs to over-express IL-7 and IL-12 may shift the chronic inflammatory profile in the tumor microenvironment to favorable Th1/Th17 for an acute CART cell response by improving and amplifying the antitumor CART cell response [256]. The gene discussed is IL7; the disease is neoplasm.